An Open-Source Web-Based Viewer for Disseminating Image-Derived Models

Christian Herz; Kyle Sunderland; Matthew Daemer; Julia Iacovella; Sehdev Pressley; Ashley Koluda; Csaba Pinter; Kevin Zuber; John Daniels; Allen Ladd; Mali Hetmaniuk; Kevin K. Whitehead; Andras Lasso; Matthew A. Jolley

arXiv · 2610.19237

An Open-Source Web-Based Viewer for Disseminating Image-Derived Models

Christian Herz·Kyle Sunderland·Matthew Daemer·Julia Iacovella·Sehdev Pressley·Ashley Koluda·Csaba Pinter·Kevin Zuber·John Daniels·Allen Ladd·Mali Hetmaniuk·Kevin K. Whitehead·Andras Lasso·Matthew A. Jolley

View original source ↗Read source document ↗Export metadata ↓

Abstract

Patient-specific 3-dimensional (3D) models are increasingly central to planning surgery and catheter-based intervention in children with congenital heart disease (CHD), whose anatomy is often atypical and variable. These models inform care only when the surgeons and interventional cardiologists who make treatment decisions can rotate, crop, and measure them directly. Desktop modeling applications require local installation, capable hardware, and training. Commercial web-based viewers are portable but closed, and, in our experience, cannot display volume rendering, time-resolved (e.g., 4-dimensional) data, or the custom workflows centers build for CHD. Because CHD populations are small and heterogeneous, such workflows are unlikely to be prioritized commercially, and end users have no means to add them. To address these limitations, we developed the SlicerHeart Viewer, an open-source module that presents a simplified interface to a complete 3D Slicer/SlicerHeart session running on a server. Clinicians access models created by clinical modeling services from any device through a web browser. Because 3D Slicer runs underneath, volume rendering, time-resolved data, and any SlicerHeart workflow, including those developed for CHD, are available without modification. The module is independent of the hosting environment; we chose internal servers behind institutional single sign-on, and a cloud-hosted option is in development. Over one year at a single pediatric center, nearly all of 82 modeled cases were shared through the Viewer with clinicians from five specialties, with cases loading in 5 to 10 seconds. The approach is not specific to CHD and is deployable at other centers.

Explore related subjects

q-bio.QM

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Christian Herz, Kyle Sunderland, Matthew Daemer, Julia Iacovella, Sehdev Pressley, Ashley Koluda, Csaba Pinter, Kevin Zuber, John Daniels, Allen Ladd, Mali Hetmaniuk, Kevin K. Whitehead, Andras Lasso, Matthew A. Jolley. 2026-10-19. An Open-Source Web-Based Viewer for Disseminating Image-Derived Models. https://arxiv.org/abs/2610.19237

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

gpuGEM: GPU-based linear optimisation of genome-scale metabolic models

Summary: Genome-scale metabolic models increasingly challenge CPU linear-programming solvers in repeated optimisation. We present gpuGEM, an open-source Python library for GPU-based optimisation using NVIDIA cuOpt, with size-adaptive settings validated against HiGHS and Gurobi. Across ten models spanning four orders of magnitude, gpuGEM achieved 1.1x to 94x speed-ups over the faster HiGHS method (dual simplex or interior point), and outperformed Gurobi on three models (1.6x to 2.5x). In candidate-gene prioritisation, gpuGEM reduced end-to-end query time from 41 s to 21 s. Availability and Implementation: gpuGEM is released under the MIT licence at https://github.com/Digital-Metabolic-Twin-Centre/gpuGEM and on PyPI (pip install gpugem); release v0.1.3 is archived at https://zenodo.org/records/23422813. It requires an NVIDIA GPU of compute capability 7.0 or newer (Volta onward), Python 3.11 or later, CUDA 12 and cuOpt 26.6 or later. Contact: ronan.mt.fleming@gmail.com Supplementary information: Supplementary data are available as an ancillary file on arXiv.

q-bio.QM↗

arXiv2026

The Verification Wall in Microbial Metabolomics

Computational methods now propose structures for gut microbial metabolites faster than any laboratory can confirm them. We argue that verification, not generation, is the binding constraint, and that better models will not relieve it. Confirming a structure to the field's own standard means having the molecule in hand. Automation can lower what that costs per compound, but the cost stays proportional to the number of structures and never amortizes across them. Two substitutes are on offer and neither removes that requirement. In-silico spectral prediction ranks candidates instead of confirming one, and the strongest current model puts the right structure first 33.5% of the time on a scaffold-split benchmark. Any assignment resting on spectral similarity is, by the field's own definition, made without a reference standard. Microcrystal diffraction does return a structure, but it needs the compound to crystallize out of a trace mixture, which is a different problem rather than an easier one. We sorted 10,645 computationally inferred metabolite structures by what verifying each would take. Between 5% and 37% have no verification route identified under our analysis. That spread reflects where the thresholds are set rather than a measured count of unverifiable compounds, and the inaccessible ones cluster among the most speculative entries. Those figures understate the problem, because the gut makes far more compounds than any database records. HMDB holds only what someone has already thought worth cataloguing, and structure generators are bounded by nothing at all. The claim is easy to disprove. Show a route that confirms structures as fast as they are proposed. Until someone does, two problems stay unsolved. Nobody knows how to spend a verification budget that will always be too small, or what a biologist may conclude from a structure that was never confirmed.

q-bio.QM↗

arXiv2026

PCR-ALERA: A PCR-ELISA analogue but antibody-free DNA detection system

PCR-ALERA is a new concept for DNA detection that combines DNA amplification by polymerase chain reaction (PCR) with an activator-linked enzyme reactivation assay (ALERA). PCR-ALERA resembles the commercial, semi-quantitative PCR-ELISA assay that offers high sensitivity and high-throughput screening in microplates. PCR-ALERA overcomes a major drawback of PCR-ELISA since it does not require the time-consuming handling of expensive antibodies. In the first step of the assay, commercially available modified nucleotides were incorporated during PCR amplification of the target DNA. A selenocysteine containing peptide (the activator) was linked to the amplified DNA by click chemistry. This peptide has been optimized for the highly efficient activation of the latent protease papain by selenolate-triggered disulfide cleavage. The DNA-peptide hybrid was then immoblized in microplate wells and incubated with latent papain. The latter was readily activated and converted a fluorogenic substrate to a fluorescent product with high catalytic turnover. Overall assay time is about 4 hours including PCR.

q-bio.QM↗